Nov 08, 2026 4:35 pm EST Mineralys Therapeutics Presents New Late-Breaking Data from Transform-HTN Open-Label Extension Trial of Lorundrostat in Hypertension at AHA Scientific Sessions 2026
Nov 06, 2026 8:00 am EST Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Nov 04, 2026 4:05 pm EST Mineralys Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update
Oct 28, 2026 4:05 pm EDT Mineralys Therapeutics to Announce Third Quarter 2026 Financial Results and Host Conference Call on Wednesday, November 4, 2026
Oct 28, 2026 7:05 am EDT Mineralys Therapeutics Announces Publication of Phase 2 Explore-CKD Trial Results for Lorundrostat in Kidney International
Oct 22, 2026 6:40 pm EDT Mineralys Therapeutics Presents New Lorundrostat Data in Participants with Hypertension and Chronic Kidney Disease at ASN Kidney Week 2026
Oct 19, 2026 4:05 pm EDT Mineralys Therapeutics Expands its Board of Directors with the Appointments of Kristine Peterson and Lonnel Coats
Oct 09, 2026 9:00 am EDT Mineralys Therapeutics Presents New Data for Lorundrostat at the American Heart Association Hypertension Scientific Sessions 2026
Oct 02, 2026 4:30 pm EDT Mineralys Therapeutics Announces Presentation of New Lorundrostat Data at the American Society of Nephrology (ASN) Kidney Week 2026
